

REDACTION AND CONFIDENTIALITY LOG TO FORM HCMO-1 AND ATTACHMENTS

BATES REFERENCE	PARTY INFORMATION	INFORMATION REQUESTED	INFORMATION REDACTED	BASIS FOR REDACTION
R-CVR_INOV_HCMO_00031	CVR and Inovia Vein	<u>HCMO-1 Notice of Material Change Transaction</u>	Individual Contact Information	<p>The parties request confidential treatment of certain information provided in the HCMO-1 Notice of Material Change Transaction Form. This information has not been made publicly available in any other forum and includes contact information for individuals. (<i>See</i> ORS 192.345(23)).</p> <p>Under ORS 415.501(13)(c), The Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a “material change transaction”. As such, the parties are requesting further confidential treatment of these materials.</p>
R-CVR_INOV_HCMO_000031 And R-CVR_INOV_HCMO_00037 - R-CVR_INOV_HCMO_00043	CVR and Inovia Vein	<u>HCMO-1 Notice of Material Change Transaction</u> and <u>HCMO-1b: Business Entities Form</u>	EIN Numbers of Entities	<p>The parties request confidential treatment of certain information provided in the HCMO-1 Notice of Material Change Transaction Form. This information has not been made publicly available in any other forum and includes entity identification information. Further, this information is competitively sensitive and disclosure would enable competitors to identify and exploit vulnerabilities in the parties’ operating model. (See ORS 192.345(2)).</p> <p>Under ORS 415.501(13)(c), The Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a “material change transaction”. As such, the parties are requesting further confidential treatment of these materials.</p>
R-CVR_INOV_HCMO_00031	CVR and Inovia Vein	<u>HCMO-1 Notice of Material Change Transaction</u>	Valuation Statement	<p>The parties respectfully request that the Valuation Statement be redacted from public disclosure under ORS 192.345(2), as it constitutes a trade secret. The financial terms of the proposed transaction are part of a confidential negotiation that may or may not result in a finalized agreement and are subject to a lawful, corresponding Non-Disclosure and Confidentiality Agreement. As privately held companies, the parties have taken deliberate steps to maintain the confidentiality of this information, which has not been published, is known only to third-party advisors engaged under privilege, and to employees and contractors on a need-to-know basis with instructions not to disclose. CVR utilized proprietary valuation models and business data to develop the Valuation Statement, and competitors could use this information to gain an unfair advantage in</p>

BATES REFERENCE	PARTY INFORMATION	INFORMATION REQUESTED	INFORMATION REDACTED	BASIS FOR REDACTION
				<p>future acquisitions. Moreover, premature disclosure would compromise Inovia Vein’s ability to negotiate with other entities in the future.</p> <p>CVR devoted significant time, effort, expense, and personnel resources to assess the financial feasibility of contracting with Inovia Vein and acquiring its non-clinical assets through CVR, and its clinical assets through CVR-OR, as further described in Form HCMO-1.</p> <p>Under ORS 415.501(13)(c), The Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a “material change transaction”. As such, the parties are requesting further confidential treatment of these materials.</p>
R-CVR_INOV_HCMO_00031	Inovia Vein	<u>HCMO-1 Notice of Material Change Transaction</u>	Oregon Business	<p>Inovia Vein respectfully requests that its aggregated patient care and service data be withheld from public disclosure under ORS 192.345(2), as it constitutes confidential information and trade secrets. The information holds substantial economic value, is used for proprietary business purposes, and is kept strictly confidential through secure storage, internal policies, and binding agreements. Unauthorized disclosure could violate patient and contractual obligations, harm Inovia Vein’s competitive position, and provide an unfair advantage to competitors. Protecting this data is essential to maintaining strategic, financial, and patient integrity, and therefore qualifies for exemption from public records disclosure.</p> <p>Under ORS 415.501(13)(c), The Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a “material change transaction”. As such, Inovia Vein is requesting further confidential treatment of these materials.</p>

BATES REFERENCE	PARTY INFORMATION	INFORMATION REQUESTED	INFORMATION REDACTED	BASIS FOR REDACTION
R-CVR_INOV_HCMO_00059	CVR and Inovia Vein	<u>Term Sheet</u>	Valuation Statement	<p>The parties respectfully request that the Valuation Statement be redacted from public disclosure under ORS 192.345(2), as it constitutes a trade secret. The financial terms of the proposed transaction are part of a confidential negotiation that may or may not result in a finalized agreement and are subject to a lawful, corresponding Non-Disclosure and Confidentiality Agreement. As privately held companies, the parties have taken deliberate steps to maintain the confidentiality of this information, which has not been published, is known only to third-party advisors engaged under privilege, and to employees and contractors on a need-to-know basis with instructions not to disclose. CVR utilized proprietary valuation models and business data to develop the Valuation Statement, and competitors could use this information to gain an unfair advantage in future acquisitions. Moreover, premature disclosure would compromise Inovia Vein's ability to negotiate with other entities in the future.</p> <p>CVR devoted significant time, effort, expense, and personnel resources to assess the financial feasibility of contracting with Inovia Vein and acquiring its non-clinical assets through CVR, and its clinical assets through CVR-OR, as further described in Form HCMO-1.</p> <p>Under ORS 415.501(13)(c), The Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a "material change transaction". As such, the parties are requesting further confidential treatment of these materials.</p>
R-CVR_INOV_HCMO_00074 - R-CVR_INOV_HCMO_00076	CVR	<u>Financial Statements</u>	Financial Statements	<p>CVR requests confidential treatment of the CVR Financial Statements. As a nonpublic entity, this information has not been made publicly available in any other forum. Further, this information is competitively sensitive and disclosure would enable competitors to identify and exploit vulnerabilities in the company's operating model (<i>See</i> ORS 192.345(2)).</p> <p>Under ORS 415.501(13)(c), the Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a "material change transaction." As such, CVR is requesting further confidential treatment of its Financial Statements, unless CVR provides its written</p>

BATES REFERENCE	PARTY INFORMATION	INFORMATION REQUESTED	INFORMATION REDACTED	BASIS FOR REDACTION
				consent to publication.
R-CVR_INOV_HCMO_00077 - R-CVR_INOV_HCMO_00098	Inovia Vein	<u>Financial Statements</u>	Financial Statements	<p>Inovia Vein requests confidential treatment of the Inovia Financial Statements. As a nonpublic entity, this information has not been made publicly available in any other forum. Further, this information is competitively sensitive and disclosure would enable competitors to identify and exploit vulnerabilities in the company's operating model (<i>See</i> ORS 192.345(2)).</p> <p>Under ORS 415.501(13)(c), the Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a “material change transaction.” As such, Inovia is requesting further confidential treatment of its Financial Statements, unless Inovia provides its written consent to publication.</p>
R-CVR_INOV_HCMO_00107 - R-CVR_INOV_HCMO_00251	Inovia Vein	<u>Governance Documents</u>	Operating Agreement	<p>Inovia Vein requests confidential treatment of certain information provided in its Governance Documents. This information has not been made publicly available in any other forum. Further, this information is competitively sensitive and disclosure would enable competitors to identify and exploit vulnerabilities in Inovia Vein’s operating model. (<i>See</i> ORS 192.345(2)).</p> <p>Under ORS 415.501(13)(c), The Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a “material change transaction”. As such, Inovia Vein is requesting further confidential treatment of these materials.</p>